MN551 Unit 4 immune response case example

Fever, Arthralgia and Rash Nine Days After Crotalidae Antivenom: Arguing From Timing and Complement to a Type III Mechanism

[Student Name]

Purdue University Global

MN551: Advanced Physiology and Pathophysiology

Unit 4 Assignment

[Instructor Name]

[Date]

Composite case written as a model document. No real patient, hospital or clinician is described.

The Case as Supplied

A composite 47-year-old fencing contractor was bitten on the left calf by a rattlesnake while clearing brush. He received ovine Crotalidae polyvalent immune Fab antivenom in the emergency department, his swelling and coagulation values stabilized, and he was discharged on day three. On day nine he returns with a temperature of 38.4 C, aching in both knees and wrists, and a rash of red, slightly raised papules running along the lateral borders of both feet where the plantar skin meets the dorsal skin. He reports no new medications, no wheezing and no throat tightness.

The laboratory panel on day nine shows C3 at 62 mg/dL and C4 at 8 mg/dL, both below the laboratory's reference ranges, an erythrocyte sedimentation rate of 48 mm/h, and a urinalysis with 1+ protein and a few red cells but no casts. The complete blood count is unremarkable apart from mild neutrophilia. The bite wound is healing without signs of infection.

The question the case poses is not what to call this illness but how an injection given nine days earlier produced fever, joint pain, a rash and protein in the urine at the same time, in four tissues that have nothing obvious in common.

Three Observations That Carry the Argument

The first observation is timing. The reaction began nine days after exposure, not minutes or hours after it. A primary antibody response requires antigen presentation, T cell help, B cell proliferation and class switching, and IgG against a new antigen typically becomes measurable toward the end of the first week (Abbas et al., 2022). An onset at day nine fits the time needed to make antibody against a protein never met before, and it immediately separates this illness from reactions that need no new antibody at all.

The second observation is complement. C3 and C4 are both low. A reader could interpret low complement as weakness of the immune system, but the context points the other way. This man had no history of recurrent infection before the bite, and his values were drawn during an acute inflammatory illness. Low C3 and C4 in a patient who is actively inflamed indicate a cascade that is running and consuming its own components, not one that was never there. The classical pathway, which consumes C4 as well as C3, is activated when antibody bound to antigen engages C1q, so falling C4 also points toward antibody-antigen complexes as the trigger.

The third observation is distribution. Fever, joints, skin and kidney do not share an organ, but they share a vascular feature. Glomeruli filter plasma under high pressure, synovium is supplied by fenestrated capillaries, and the dermal venules of the feet sit where hydrostatic pressure is greatest in an upright person. Material carried in the blood that can leave it where flow is filtered or turbulent would reach all of these sites.

Mechanism: From Foreign Protein to Deposit

The antivenom is made of antibody fragments raised in sheep. To this patient's immune system those fragments are foreign proteins, and a normal primary response produces IgG against them. The timing of that response is what creates the disease. When the new antibody first appears, a large amount of foreign protein is still circulating, so antigen outnumbers antibody. Under these conditions of antigen excess, each antibody binds only a few antigen molecules, and the complexes that form are small and soluble (Rogers, 2023).

Size decides what happens next. Large lattices formed near equivalence are efficiently bound by complement receptors on red cells and removed by phagocytes in the spleen and liver. Small soluble complexes escape that clearance and remain in the circulation long enough to deposit where plasma is filtered: in glomerular capillaries, in the synovial vasculature and in the walls of small dermal vessels. Once lodged, the complexes fix complement through the classical pathway. C3a and C5a increase vascular permeability and draw neutrophils, and neutrophils bind the deposited IgG through Fc receptors, releasing enzymes and oxidants that injure the vessel wall. That local inflammation produces the joint pain, the palpable rash and the protein and red cells in the urine, while circulating cytokines produce the fever.

The severity at each site follows how much material settled there and how long it stayed. In the kidney, the 1+ protein and scattered red cells without casts indicate small deposits along the glomerular capillary wall that provoke limited inflammation, not the dense deposits and crescents of a sustained immune complex glomerulonephritis. The joints ache and stiffen without effusion because synovial deposits recruit neutrophils briefly and are cleared. The rash along the edges of the soles is the most specific sign in the case. The line where plantar and dorsal skin meet is where standing pressure and small-vessel density are both high, and eruptions in this band have been described repeatedly in serum sickness after foreign protein therapy. None of these sites needed to be the target of the antibody; each became involved because of where complexes leave the blood. The fever has a systemic source rather than a site: complement fragments and activated neutrophils release interleukin-1 and tumor necrosis factor, which act on the hypothalamus to raise the temperature set point.

The same mechanism explains why the illness ends. As antibody production increases, the balance shifts toward equivalence, larger complexes form and are cleared, and the foreign protein is removed from the circulation. When no antigen remains, no new complexes form. Complement levels recover over the following weeks, and the reaction resolves without lasting injury in most patients. Lavonas et al. (2011) note that delayed serum sickness after Fab antivenom is usually self-limited, which is what the mechanism predicts.

Rejected Mechanisms, by Name

An immediate hypersensitivity, type I, would require preformed IgE on mast cells and would have begun within minutes of the infusion with urticaria, bronchospasm or hypotension. It cannot account for a nine-day delay in someone with no prior exposure to sheep protein. A type II reaction, antibody against a fixed antigen on a particular tissue, would target one tissue and would not consume complement in the circulation in this scattered way. A type IV reaction, mediated by T cells rather than antibody, would lack consumed complement entirely and would usually present as localized dermatitis or granulomatous inflammation.

Only a type III mechanism in the Gell and Coombs classification accounts for all three observations: the time needed to make IgG, complement consumed by the classical pathway and a distribution that follows small vessels rather than one organ. The classification is useful here because the paper reaches it at the end. Named at the start, it would have organized the evidence; named after the evidence, it is supported by it. Serum sickness from other therapeutic proteins, including monoclonal antibodies, shows the same triad of fever, rash and arthralgia and the same timing, which supports the view that the mechanism belongs to the foreign protein and not to the snake venom (Karmacharya et al., 2015).

References

Abbas, A. K., Lichtman, A. H., & Pillai, S. (2022). Cellular and molecular immunology (10th ed.). Elsevier.

Karmacharya, P., Poudel, D. R., Pathak, R., Donato, A. A., Ghimire, S., Giri, S., Aryal, M. R., & Bingham, C. O. (2015). Rituximab-induced serum sickness: A systematic review. Seminars in Arthritis and Rheumatism, 45(3), 334-340. https://doi.org/10.1016/j.semarthrit.2015.06.014

Lavonas, E. J., Ruha, A. M., Banner, W., Bebarta, V., Bernstein, J. N., Bush, S. P., Kerns, W. P., Richardson, W. H., Seifert, S. A., Tanen, D. A., Curry, S. C., & Dart, R. C. (2011). Unified treatment algorithm for the management of crotaline snakebite in the United States: Results of an evidence-informed consensus workshop. BMC Emergency Medicine, 11, 2. https://doi.org/10.1186/1471-227X-11-2

Rogers, J. L. (Ed.). (2023). McCance and Huether's pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier.